HIV/HBV/HCV Test Kits Market

HIV/HBV/HCV Test Kits Market Outlook

The HIV/HBV/HCV test kits market size is projected to be valued at US$ 6,568.3 million in 2023 and is expected to rise to US$ 11,573.9 million by 2033. The sales of HIV/HBV/HCV test kits are expected to grow at a significant CAGR of 5.8% during the forecast period. Various trend positively influencing the HIV/HBV/HCV test kits market are:

A wide range of micro and macroeconomic factors are influencing the growth of the HIV/HBV/HCV test kits market. The most influential factor is the extensive awareness campaigns carried out by various non-governmental organizations around the world.

These non-governmental organizations are attempting to reach out to people in remote areas and educate them about immunodeficiency diseases and the methods for detecting and preventing them. This has resulted in a significant increase in global demand for HIV/HBV/HCV test kits.

One of the key development factors for the global HIV/HBV/HCV test kits market is rising demand for point-of-care testing for HIV, HBV, and HCV.

POC testing technologies are now more efficient, widely available, and reasonably priced. Early HIV detection can be extremely beneficial to the patient because it facilitates the doctor to design a more effective treatment plan.

Governments and regulating authorities all over the world have launched initiatives and campaigns to educate and treat people. They are supplying these kits for free in order to raise awareness.

Increasing investments by leading players to make these HIV/HBV/HCV test kits more efficient, reliable, and affordable has contributed to the global market's overall growth. The ease of use of these test kits has increased their popularity in medical centers and hospitals.

Regardless of the various factors influencing the growth of this market, there are several key issues that must be addressed in order to facilitate future growth. The relatively high total costs of developing and using HIV/HBV/HCV test kits, as well as reimbursement policies, are limiting the market's growth.

However, the market is expanding as a result of rising product approvals, alliances, and acquisitions by major companies.

How The Market Progressed till June 2022?

The comparative analysis and market growth rate of global HIV/HBV/HCV test kits market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 20 BPS. Furthermore, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 30 Basis Point Share (BPS).

The decline in the BPs values observed can be attributed to the disruptions in supply chain and distribution networks globally due to the global pandemic. Moreover, the availability of self-test kits is limited to the developed nations, and thus poses a dip in demand, owed to the high disease epidemiology in the developing nations and the high demand generated through the same.

The key developments in the market include the launch of a real-time fluorescence PCR technology used for nucleic acid qualitative detection of HBV, and chip-based assays for HCV, such as the Truenat HCV.

Growing disease epidemiology of viral and infectious diseases, and the increasing efforts by regional governments to extend outreach for detection is anticipated to provide a positive growth outlook for the market during the projected period.

2018 to 2022 HIV/HBV/HCV Test Kits Market Outlook in Comparison to 2023 to 2033 Growth Forecast

The world has seen significant increase in incidence of HIV and hepatitis, and this is expected to majorly drive HIV/HBV/HCV test kit consumption. With HIV and hepatitis infections being a major public health issue across the world, demand for efficient diagnostic services for these diseases is prominent.

Sales of HIV/HBV/HCV test kits rose at a CAGR of 6.8% from 2018 to 2022. Governments and NGOs across the world are taking initiatives to raise awareness about STD testing and its importance in the fight against HIV and hepatitis. This has led to substantial increase in awareness on a global level, with initiatives such as 'Start Talking. Stop HIV'.

Rising research & developments in the medical diagnostics industry, increasing incidence of HIV and hepatitis, increasing awareness among the general population, rising healthcare expenditure, technological advancements in diagnostics, etc., are some major factors that are expected to drive consumption of HIV/HBV/HCV test kits.

Demand for HIV/HBV/HCV test kits is expected to be majorly influenced by developing and emerging markets, with low- and middle-income countries such as Brazil, India, and China leading the way.

Lack of awareness and inadequate availability of test kits in less-developed economies is expected to restrain demand for HIV/HBV/HCV test kits to a certain extent. Market witnessed a significant downfall during the pandemic period as supply lines were cut short. Nevertheless, the market is anticipated to recover swiftly and contribute a US$ 11,573.9 million revenue share by 2033.

Overall, the HIV/HBV/HCV test kits market is predicted to expand at a CAGR of 5.8% from 2023 to 2033.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Key Trends are Expected to Majorly Influence Demand for HIV/HBV/HCV Test Kits?

Innovations and Product developments

The burden of HIV, HBV, and HCV infections is still disproportionately high in developing economies (India, sub-Saharan Africa, Brazil) where co-infection rates are high. For HIV, HBV, and HCV serological testing, high analytical performance multiplex rapid diagnostic techniques may improve the cascade of screening and lead to more cost-effective linkage to care. Such a testing strategy may be especially beneficial for hard-to-reach high-risk populations and may also increase the impact of self-testing on public health. For instance, the prototype Triplex HIV/HCV/HBsAg finger-stick whole-blood self-test may provide a simple, quick, and inexpensive way to detect HIV, HBV, and HCV infections. It might be particularly useful for enhancing the detection of three closely related endemic viral diseases. These choices might boost screening programs, reducing the price of diseases brought on by untreated HIV, HBV, or HCV infections in the future. They might also help with efforts to treat these infections and perhaps even eradicate HCV infection.

Which Restraining Factors Could Impede Market Growth?

Lack of Awareness to Hinder Sales of HIV Test Kits

Awareness about the treatment of HIV in less developed economies such as Brazil, India, and African nations is very limited due to lack of developed healthcare infrastructure. This has adversely affected HIV/HBV/HCV test kit sales in these economies and restrained overall market potential on a global level.

The asymptomatic nature of infections has also hampered the HIV/HBV/HCV test kits market. Poor healthcare facilities, high costs of treatments and medicines, and low STD testing are some other factors that may restrain HIV test kit sales over the forecast period.

Country-wise Analysis

Growing preference for rapid screening is anticipated to stimulate sales of rapid HIV test kits in the country.

HIV has been a public health issue in the United States for quite some time, and while the number of new cases has decreased over the past decades, the rate of new infection detections remains a source of concern. Advanced healthcare infrastructure, increased patient awareness, and rising adoption of effective rapid testing kits are some of the major factors driving the HIV/HBV/HCV testing systems market in the United States.

Canada is expected to account for US$ 479.0 million of the North American HIV/HBV/HCV Test Kits market.

Canada is expected to have a significant share due to advanced diagnostic tools, high awareness of disease and diagnostic devices, a strong presence of industry players in the region, improved healthcare infrastructure, and increased awareness among healthcare industry stakeholders about available technologies in the region. For example, the Public Health Agency of Canada investigated 28 cases of severe acute hepatitis in children in Canada that met the national case definition between April and September 2022. As a result, an increase in hepatitis cases is expected to lead to an increase in diagnostic testing, ultimately driving market growth in the region.

Over the next few years, the Asia Pacific market for HIV/HBV/HCV test kits is expected to grow rapidly.

The region's ever-increasing population is the primary driving factor for the market. China and India are two of the world's most densely populated countries in Asia Pacific. A dense population is more likely to be infected with an immunodeficiency virus. Naturally, awareness and availability of HIV/HBV/HCV test kits are expected to grow in the Asia Pacific market.

India is the world's second-most populous country and ranks third in terms of HIV infections, with over 2 million people infected. Instances of new HIV infections have decreased in recent decades, but they remain a source of concern given the country's large population.

Increasing STD testing awareness and developing healthcare infrastructure are expected to have a significant impact on HIV/HBV/HCV test equipment demand in India. Over the next few years, the market in India is likely to remain extremely profitable for HIV/HBV/HCV test kit providers.

HIV/HBV/HCV Test Kits Market - Category-wise Insights

Relative to conventional testing, assays have been proved to deliver reliable results, even with microscopic samples.

Segment to witness a growth of 6.4% during 2023 to 2033

In 2022, the assay-based test kits segment held the major share of the market. Assay kits are the first line of patients testing which is naturally stimulating its growth. Furthermore, in most developing countries, healthcare professionals and patients rely on assay-based testing results. Besides, there have been advancements in assay-based test kits. The Xpert HCV Viral Load Fingerstick Test from Cepheid, for example, is a point-of-care test that employs the GeneXpert System. This point-of-care test looks for HCV RNA in finger-stick whole blood capillaries (or assay). This type of HCV testing involves drawing capillary blood from the patient via finger prick into a Minivette collection device, which is then processed in a GeneXpert device at or near the point-of-care testing location.
Blood sample tops the sample segment and is expanding at a rapid rate of 6.1% CAGR during the forecast period.

Blood samples are highly prevalent in testing or diagnosis procedures due to ease in storing and their high reliability on patients sample profile. Most AIDS and AIDS-related complex (ARC) patients, as well as many asymptomatic individuals belonging to high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The presence of these HIV antibodies in human blood and plasma samples is frequently tested using enzyme-linked immunosorbent assays (ELISA). INNO-LIA HIV I/II Score, for example, is a Line Immuno Assay (LIA) that detects the presence of antibodies against HIV-1, including group O and HIV-2, in human blood or plasma. INNO-HIV LIA's I/II Score distinguishes between HIV-1 and HIV-2 infections. It is intended to be used in conjunction with an anti-HIV screening process on reactive specimens. As a result, demand for assay-based test kits has increased.

Competitive Landscape

Given the presence of a few companies operating globally and regionally, the HIV/HBV/HCV test market is slightly fragmented. The competitive landscape includes an examination of a few well-known international and local companies that hold market share. Abbott Laboratories, Danaher Corporation, BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin S.p.A, F. Hoffmann-La Roche AG, Hologic Inc, MedMira Inc, Qaigen Inc, Grifols SA, Sysmex Corporation, and Siemens Healthineers are key market players.

• Gilead Sciences, Inc. joined a public-private partnership with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration of Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center, in September 2022. The multi-year initiative to take a phased approach to addressing barriers to viral hepatitis diagnosis and care in primary healthcare institutions in Vietnam and the Philippines, both of which have high hepatitis B and C burdens.
• Roche introduced the Elecsys HCV Duo immunoassay in July 2022. Elecsys HCV Duo is one of the first commercially available immunoassays that can determine hepatitis C virus (HCV) antigen and antibody status simultaneously and independently.

Scope of Report

HIV/HBV/HCV Test Kits Market by Solution

HIV/HBV/HCV Test Kits Market by Test Kit Type:

• Assay-based Test Kits
• Rapid Test Kits

HIV/HBV/HCV Test Kits Market by Sample:

• Blood
• Urine
• Saliva

HIV/HBV/HCV Test Kits Market by End User:

• HIV/HBV/HCV Test Kits for Hospitals
• HIV/HBV/HCV Test Kits for Clinics
• HIV/HBV/HCV Test Kits for Diagnostic Laboratories
• HIV/HBV/HCV Test Kits for Government Organizations and NGOs
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia & Pacific
• East Asia
• Middle East & Africa (MEA)